Patent Grant
12102512
Embodiments of the present invention relate to apparatuses, methods, devices, and systems for use in the treatment of wounds by topical negative pressure (TNP) therapy.
In recent years TNP therapy has become increasingly important in the field of improved treatment of wounds by making the healing thereof faster and more controlled.
The basic principle of TNP therapy is to create a closed cavity over the wound itself by means of a thin, flexible sealing film adhered to the patient's sound skin surrounding the wound; admitting one end of an aspirant conduit into the closed cavity, the conduit being sealed to the flexible film, for example; and connecting a distal end of the aspirant conduit to a vacuum source such as an electrically driven vacuum pump, for example, to create a pressure lower than the surrounding ambient atmospheric pressure within the wound cavity. As is known to the skilled person the lower pressure creates many beneficial therapeutic effects on the wound including increased blood flow to the wound and faster granulation of tissue, for example. There are very many variations on this basic principle of TNP therapy.
The types of wounds treated by TNP therapy generally range from quite small at about 5 cm2 to very large traumatic wounds and burns of no particular maximum dimension. Such wounds may also have significant depth and therefore, significant volume. It is necessary to control the way in which a wound heals. For example, the wound should heal from the base up and close in from the edges desirably in a uniform manner. In particular it is desirable that the wound does not close over and form an occluded cavity in the flesh which is extremely undesirable from the patient's point of view as such form sites for infection.
To prevent the formation of occluded cavities during TNP therapy, the wound is usually packed with a filler which desirably has some resilience or “bounce” to resist the compressive forces created during TNP therapy by outside ambient atmospheric pressure bearing down on the wound due to the vacuum created in the wound cavity. The purpose of the filler is to keep the surrounding edges of the wound apart so that they cannot grow over and form a cavity. The filler may also perform the function of providing fluid flow channels between the wound and the filler in order to provide a uniform reduced pressure distribution over the surface area of the wound and to promote efficient aspiration of exudate fluids away from the wound surface and generally into a remote waste receptacle associated with the aspirant conduit.
As noted above there are very many variations on the basic TNP therapy principle and to illustrate how complex TNP therapy may be reference is made to the documents described below and which are of common ownership herewith.
TNP therapy often involves the provision within a dressing to which a negative or a positive pressure is applied a bag member (sometimes also referred to as a bladder) which may be used to at least partially fill a volume of a wound, for example. Furthermore, fluctuating pressure or pressure cycling may be applied to the bag member in order to work the tissue in and around the wound region for therapeutic reasons, for example.
There are many commercially available bag members which may be included in a wound dressing, however, commercially available bag members suffer from the disadvantage that they are obviously of predetermined size and shape, for example, and there may not be available a bag member of a corresponding form to that of the wound which needs treatment. Such unavailability may not be just the unavailability in the particular hospital formulary or store, for example, but a suitably sized and shaped bag member may not be available at all commercially.
In International patent application, WO 2004/037334, apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, this application describes the treatment of a wound by the application of topical negative pressure (TNP) therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.
In International patent application, WO 2005/04670, apparatus, a wound dressing and a method for cleansing a wound using aspiration, irrigation and cleansing wounds are described. Again, in very general terms, this application utilises a similar apparatus to that in WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound.
In International patent application, WO 2005/105180, apparatus and a method for the aspiration, irrigation and/or cleansing of wounds are described. Again, in very general terms, this document describes similar apparatus to the two previously mentioned documents hereinabove but with the additional step of providing means for the supply and application of physiologically active agents to the wound site/dressing to promote wound healing.
The contents of the above references are hereby incorporated by reference in their entireties.
In spite of the self-evident growing complexity of TNP therapy, in general the field of wound fillers, which are a vital element in the therapy, has changed or improved very little over the years that TNP therapy has been developing. Aside from complicated and expensive inflatable bags, most of the fillers in use are based either on foam or on cotton gauze. Foam fillers are usually cut with scissors to the required shape (of the wound) by a clinician. However both foams and gauzes have the disadvantage that the cell or pore size is often too large and often results in growing tissue growing into the cells and adhering the foam to the wound causing further damage and trauma to the wound and patient on removal. When gauze is used as a filler, however, clinicians are instructed to “fluff up” the gauze to increase its volume which can cause problems in that the actual form of the gauze as packed into wounds is very variable. A further disadvantage with both foams and gauze when cut to fit wounds is that of debris. Gauze and foam are particularly prone to shedding fibres and particles when cut and these inevitably find their way into the wound and become occluded therein which can lead to later infection.
Foam or gauze as the wound filling medium has the additional disadvantage of tissue ingrowth into the pores of the filler and which may cause damage to newly formed granulation tissue on removal and also pain to the patient. Furthermore, such porous materials are subject to becoming saturated with wound exudate fluids causing a build up of bacteria leading to infection.
All of the wounds to which the above documents are addressed may require the provision of a bag member or bladder within a wound dressing and those currently available may be unsuitable. Indeed, International patent application WO 2004/037334 referred to above shows at
Other reasons why inflatable bladder-type wound fillers may be used is to apply an uneven or textured or otherwise non-smooth surface possessed by the bladder surface directly onto a wound surface/interface. The textured surface assists in “working” the wound surface thereby enhancing the therapeutic effect of pressure cycling. A textured surface also provides a plurality of fluid flow channels at the interface between the wound filler and the wound surface to assist in a more even (negative) pressure distribution over the wound surface and a more rapid and even drainage of fluids such as wound exudates, for example, away from the wound region towards an aspiration conduit generally forming part of a TNP therapy apparatus.
Examples of known inflatable wound fillers are described in WO-A-2005/082435 and GB-A-2378392, the entireties of both of which are hereby incorporated by reference.
In WO-A-2005/082435, an inflatable bag or bladder-type wound filling member is used to fill the wound cavity. The bladder member is described as having two layers, however, the two layers appear to be in the form of an integral structure. A problem with this type of structure is that it is difficult and costly to manufacture. The structure also makes the bladder relatively rigid and stiff and inflexible against a wound surface possibly leading to discomfort and trauma.
GB-A-2378392 describes a wound irrigation and/or suction device comprising an inflatable bladder or pouch having a plurality of flexible conduits provided within and running through the bladder interior, the conduits having outlet/inlet apertures on the bladder surface. The conduits are fluid transfer conduits to either supply fluid to the wound or to conduct fluid away from the wound or both. However, a problem with this particular construction is that it is extremely complex and costly to manufacture.
It is an object of certain embodiments described herein to overcome or mitigate some of the disadvantages of known wound fillers.
It is further intended in certain embodiments to provide a method of making a suitably sized and shaped bag member in a dressing for a particular wound from materials commonly available in most hospital formularies or stores.
According to a first embodiment there is provided a wound filling device for use in an apparatus for the application of topical negative pressure therapy to a site on the body of a mammal, the device comprising: an inflatable bag member having at least one fluid carrying conduit operably connected thereto to inflate/deflate said bag member; a separate textured covering sock member at least partially covering the inflatable bag member.
The wound filling device as described above may form part of an apparatus for the application of TNP therapy to a wound, for example, on the body of a human being. Such apparatus may also generally include an aspiration conduit connected to aspiration means such as a vacuum pump, for example, for aspirating a wound cavity defined beneath a sealing membrane or drape covering adhered to sound skin or flesh surrounding the wound and beneath which the inflatable bag member and sock member are enclosed. The at least one conduit operably connected to the inflatable bag for inflating/deflating may also pass through or under the sealing membrane or drape but in any event be sealed thereto in accordance with well known TNP dressing structures. Provision of negative pressure may be achieved by any means or methods known in the art to evacuate the wound cavity region.
The inflatable bag member may be operably connected to a suitable means for inflation thereof via the at least one conduit. Such means may include well known types of pump able to pump inflation fluid, such as air for example, into the bag and also perhaps to suck fluid out so as to either maintain a constant pressure therein or to apply a pulsating pressure regime within the bag so as to work the wound surface to achieve beneficial therapeutic effects on the wound.
Whilst the option of positive pressure inflation of the bag member is described above there is also the option of allowing the bag member to self-inflate by leaving the conduit connected thereto open to atmosphere. As the wound cavity surrounding the bag member is evacuated by a vacuum pump, for example, the bag will tend to inflate by drawing air into it purely due to the pressure differential between the wound cavity and the bag interior as the bag surfaces are drawn towards the wound surface on one side and to the inner surface of the sealing drape membrane on the other side.
The wound cavity formed beneath the sealing membrane or drape may also have a further conduit provided thereto to supply an air bleed into the wound cavity so as to maintain a constant negative pressure therein to avoid undue discomfort to a patient due to excessive negative pressures being applied where the sealing membrane is particularly effective in sealing the wound cavity. Such a bleed conduit will also promote continuous aspiration of the wound cavity. Such an additional conduit may also serve the dual purpose of be used to measure pressure at the wound when a pressure transducer is connected to it distal to the wound.
A further conduit may be provided having access to the wound cavity region for the provision or application of an irrigant and/or medicaments to the wound site.
The inflatable bag member and the sock member may be mutually slideable relative to each other. Thus, as the bag member is inflated and deflated in a predetermined pressure pulsing regime, for example, the outer surface of the bag member and the inner surface of the sock member may slide against one another. This prevents the textured surface of the sock member from being forced to slide against the wound surface and causing possible trauma thereto and potentially damaging newly formed granulation tissue and thus, the outer textured surface of the sock member may apply pressure pulses substantially normally to the wound surface.
By providing the inflatable bag member and the textured sock member as two separate items made by known economic manufacturing techniques, several advantages are gained. Firstly, the inflatable bag member may be made from inherently soft and flexible thin sheet material which remains so even when having folds and convolutions when inside the wound cavity thereby imposing a minimum of unnecessary stress and trauma on the wound surface compared with known multi-layer bag constructions. The material from which the inflatable bag member may be made may be relatively very thin since the pressures which it is configured to withstand on inflation are relatively low. Secondly, by having a separate sock member over the inflatable bag member, the sock member surface texturing may be tailored to the requirements of the wound surface and have a suitable sock/wound interface design adapted to the wound type.
The sock member may be made from two sheets of material having substantially coterminous outer shapes, for example, and be welded together at their outer peripheries. One sheet may have an aperture, for example, in the centre through which the inflatable bag member is to be inserted, and also about which aperture the sock member may be turned inside out so as to contain the welded periphery on the inside of the sock member out of contact with the wound surface.
The inflatable bag member may be made from thin, flexible, substantially impervious plastics sheet material such as EVA, PU, PP, PE, silicone and any other suitable flexible plastics materials, for example, in similar manner to the sock member in that after welding it may be turned inside out to contain the weld on the inside. However, this is optional as the inflatable bag member is contained within the sock member so preventing the welded periphery from contacting the wound.
Thus, by having separate bag and sock members, the components may be made having properties which are optimised for its function and not compromised by having to fulfill two separate roles.
In one embodiment of an inflatable bag member and sock member the sheets from which they are made may be circular, for example.
The sock member may be moulded as an entity for subsequent combination with the inflatable bag member.
The conduit for inflating/deflating the bag member may be sealed to the bag member where it passes into the interior thereof. However, in a preferred embodiment, the inflatable bag member is provided with an aperture to which is affixed, by welding for example, a port member which may provide fluid access to the inflatable bag member and advantageously, fluid access to and from the wound cavity region. Such a port member may have provision for joining suitable fluid conduits such as flexible plastics materials conduits. The port member may also advantageously be provided with a suitable shroud member which serves the dual purpose of providing a smooth rounded surface which does not cause discomfort to a patient should it be lain upon and also maintaining a free flow of fluids from the wound site without the various ports being occluded or blocked by the overlying sealing drape membrane. The port member and shroud provides the advantage of having some or all of the conduits grouped together and being able to handle the group of conduits as one which makes application of the apparatus to a wound quicker and more efficient and improving the reliability of the TNP apparatus.
In a preferred embodiment, when in use, access of the various conduits to the wound cavity region below the sealing drape may be provided by a dressing and grommet combination as described in GB patent application 0712735.0 and PCT/US 2007/074374 of common ownership herewith, the entireties of which are hereby incorporated by reference.
The construction of the device according to one embodiment uses a soft and flexible sock material allows easier dressing removal since the sock may be made from material substantially non-adherent to the wound surface thus causing less distress and trauma to the patient.
The separate sock member embodiment promotes a reduction in tissue growth tending to close the wound and leave a cavity. The sock member effectively forms an analogous member to wound fillers in conventional TNP therapy of preventing wound overgrowth and minimising the formation of pockets within the tissue and encouraging the wound to heal by secondary intent or from the wound base upwards.
The textured surface of the sock member may primarily be present to provide a plurality of channels over the surface of the bag/sock combination so as to provide an even pressure distribution over the whole surface area of the wound and also to provide by the same plurality of channels efficient and rapid drainage of wound exudate fluids therefrom.
In one embodiment of a sock member the textured surface may comprise an array of hexagonal indentations or depressions in the sock material surface effectively producing a three-dimensional surface structure, some or all of the indentations or depressions having a perforation located substantially at its centre to allow fluid flow, both gaseous and liquid, over both surfaces of the sock member, i.e. between the wound surface and sock surface and between the inflatable bag surface and sock surface. A suitable material from which the sock member may be made may be a vacuum formed plastics sheet material such as, for example, EVA film which is soft and non-adherent to a wound surface.
The sock member may have any desired surface topography and formations which are conducive to wound surface therapy.
Alternative materials from which the separate sock member may be formed may comprise woven materials, non-woven fibrous sheet, foams, electrospun nano fibres from a wide variety of different materials such as EVA, PU, PP, PE, silicone, carbomethoxy cellulose, polyacrylate, for example.
Bio-degradable materials such as collagen, oxidized cellulose, chitosan, polyglycolic acid and the like may be used, for example.
In one embodiment the inflatable bag member, port and shroud members, conduits, an appropriate dressing and grommet member for attachment to a patient and sock member may be supplied as one integrated unit which merely needs to be applied to wound and connected to suitable sources of vacuum and inflation fluid to be put into effect as TNP therapy apparatus.
According a second embodiment there is provided a wound filling device comprising a non-porous bag member, the bag member being sealed against ingress of wound exudate and being filled with resilient, compressible material.
Desirably, the bag member may be provided with a surface texture such as may permit the provision of a uniform vacuum pressure distribution, when used in TNP therapy, over the surface of a wound bed and also allow wound exudate to be drawn from some or all parts of the wound bed towards an aspiration conduit so as to be removed from the site of a wound.
Suitable surface textures may be provided by, for example, but not limited to pimples, channels and ribs and the like formed on the bag member surface. The gaps and channels formed between protrusions of various types on the bag surface permit a uniform pressure distribution over the area of the wound bed and also provide fluid pathways to permit wound exudate to be drawn around the bag member rather than through it as with prior art wound fillers and be aspirated away from the wound site.
The textured surface also applies micro-stresses to the wound bed surface and which has been shown to stimulate tissue growth and wound healing.
Advantageously it has been found that fluid channels and pathways on the surface of the bag member may be of the order of about 0.5 to 2.0 mm with struts (i.e. ridge members, for example, between channels) of the order of 0.1 to 1.0 mm. A non-limiting example may be upstanding cylinders on the bag member surface of 0.2 mm diameter and 1 mm height and pitched centres of about 1 mm arranged in equilateral triangular repeated array.
Materials from which the bag member may be formed is desirably soft and conformable may suitably be selected from the group including: HDPE, PU such as Elastane SP806™, silicone, PVC and EVA, for example. The bag member may also be of laminated construction such as from, for example, Biobrane™ which comprises a layered structure of non-porous silicone rubber; a Nylon™ mesh adhered thereto; and collagen peptide particles impregnated into the Nylon fabric mesh surface which is placed adjacent the wound.
The bag member wound packing member may also advantageously be treated with biologically active components such as silver or in addition to or in substitution of silver, antimicrobial compounds (e.g. silver containing species, iodine, guanidines, biguanidines etc.), analgesics (e.g. aspirin, ibuprofen etc.), anaesthetics (e.g. amethocaine, lignocaine etc.), growth factors (e.g. VEGF, PDGF), vasodilators (e.g. NO, sildenafil, histamine etc.) for example. Other examples of suitable active components may be found in WO 2005/105180 the content of which is included herein by reference.
In some embodiments, the bag member of the wound filling devices may optionally be soaked or coated in a non-adherent gel such as, for example, a petroleum gel an example of which is Cuticerin™, silicone gel or a hydrogel.
The resilient, compressible filling of the bag member may comprise foam or polystyrene beads, for example, however any suitable material having the desired physical characteristics may be used as the bag filling material does not come into contact with wound exudate. The bag filing material should be relatively soft but hard enough to deflect skin/tissue in the wound bed so as to stress the tissue without being too aggressive. Suitably a material hardness in the region of 70 to 100 Shore may be employed. It has been found that a plain smooth bag even with the filling may not be able to resist being pressed down into intimate contact with the wound bed by the surrounding atmospheric pressure and occluding areas of the wound from the vacuum in the wound cavity.
In some embodiments the resilient, compressible filling in the bag member may be a gas such as air or nitrogen, for example, in order to save weight on a patient in the case of a large wound. In such cases it may be desirable for the surface texturing of the bag member to be more pronounced.
Some embodiments of wound filling devices may be made to work or stress a healing wound by cycling of the vacuum applied to the wound cavity resulting in the surrounding atmospheric pressure stressing the wound bed in a cyclic manner.
A plurality of wound filling devices may be joined together in a string and a suitable number to fill a given wound be cut off from the string. Suitable material with which to string a plurality of wound filling devices together may be nylon filament which does not shed debris in the wound. A particular advantage of the wound filling devices is that they are used as units and not sub-divided and do not like foams and gauzes shed debris into the wound when cut and which debris can be occluded in a healing wound and cause later infection.
Although the bag member is sealed against ingress of wound exudate, in an embodiment of a wound filling device, the interior of the bag member may be connected by a flexible conduit to a fluid reservoir outside the wound and the covering sealing drape. The reservoir may contain a heated fluid such as warm water, for example, which may be beneficial in terms of wound healing. Alternatively, the reservoir may contain a cooled fluid which in some circumstances may be more beneficial to the wound healing process. Some circulation of the fluid may be achieved by pressure cycling of the vacuum in the wound cavity which may cause fluid to be drawn into the bag member in one cycle and be expelled in the following cycle. Thus, if the fluid in the reservoir is temperature controlled so may the fluid in the bag member in the wound.
According to a third embodiment there is provided an apparatus for the application of topical negative pressure therapy to a site on the body of a mammal and which apparatus embodies the wound filling device of the first and/or second embodiments.
According to a fourth embodiment there is provided a method of making a three-dimensional wound packing member, the method comprising the steps of: taking material selected from at least one of the following forms comprising perforated sheet, net, woven, non-woven and knitted material; subjecting the at least one material to at least one forming process selected from the processes comprising rolling into tubes, braiding, knotting and knitting to form a three-dimensional and resilient structural unit member for packing into a wound.
Certain embodiments may also comprise a further step of linking together a plurality of the structural units so formed into a chain, for example, by thread means. The chain so formed may then be used to pack a wound for TNP therapy. However, if the chain so formed provides too much volume then it may be reduced by removing a suitable number of chain units until of the appropriate overall desired volume is achieved. The linking thread means may, for example, be a monofilament thread such as Nylon™, for example, so that cutting of the thread does not create any shedding or loose fibres.
Some embodiments comprise a method of making 3 dimensional wound packing means with variable pore size and compressibility from flat sheet material, for example. By taking sheet/net/woven/non-woven/knitted material and braiding, knotting or knitting and/or forming into tubes it is possible to create 3 dimensional structures with variable but controlled open volumes and densities. It is further possible to tie units of these structures so formed together into strings or chains with linking means to form larger structures. By changing the pore size, width of material between pores and thickness of the sheet/nets it is possible to vary the compressibility and pore size of the 3D structure. The user may vary the volume of the packer by adding suitable numbers of units of wound packing members together in a wound and in the case of strings may cut the appropriate volume of packing members at the linking entities. The packing members may be used as a general wound packer, or in conjunction with a sealing means and vacuum conduit as a packer for TNP therapy of wounds where it is essential that an even distribution of pressure takes place together with allowing for contraction of the wound, and intermittent contact of the wound with the packing member.
The selected material may be rolled, for example, into a tube or strand and that tube or strand with others may then be plaited, braided, knitted or woven for example, into a 3D structural member unit having controlled resilience and porosity. In an alternative structural wound packing member embodiment, a rolled tube of the selected material may then be further rolled along the axis of the tube in the manner of a ladies stocking, for example, so as to form a doughnut or ball shape depending upon the tightness of the starting rolled tube. A plurality of such doughnuts or balls formed in this manner may also be linked together to form a chain or string.
In some embodiments relating to linking a plurality of individual wound packing member units together, when a specific number of units is cut from a chain of units, then when these are removed from a wound at a time of dressing change then they may be removed together while reducing the likelihood of units remaining hidden in a deep wound, for example, as there is with a plurality of unconnected wound packing members.
An important advantage of certain embodiments of wound packing member units is that they may be made from materials which do not naturally adhere to a wound surface such as, for example, polyurethane, polypropylene, ethylvinylacetate, silicone and the like. Further advantages of such material are that they do not shed fibres or particles when formed as extruded sheet or thermo-bonded net.
The packing member units so formed may be engineered to provide desired characteristics of porosity, compressibility and volume by controlling the degree of porosity/perforation in the initial starting sheet, for example, then controlling the degree of tightness with which the sheet is rolled, for example, and then controlling the degree of tightness with which a plurality of the rolled tubes are then braided or plaited or knitted together, for example.
Compressibility of the types of material contemplated as wound packing members may typically lie in the range from 0.01 to 0.5 kgf/cm2, preferably from 0.025 to 0.050 kgf/cm2 when measured at a compression deflection point of 40% according to DIN 53577. The materials remain freely porous to the flow of wound exudate at a compression pressure of 0.16 kgf/cm2. Typically a material would deflect to about 50% to 90% of the relaxed volume at a pressure of 0.16 kgf/cm2 and recover to about 90% of the original volume upon pressure release.
Integrity of the braided, plaited, knitted wound packing member units may be preserved by the additional step of adhesively bonding, heat sealing or tying with monofilament thread the ends of the units to prevent unraveling, for example.
It is intended that wound packing unit members are used as formed and not subdivided by cutting into smaller units which would to an extent defeat the object of eliminating shedding of particles into a wound.
According to a fifth embodiment there is provided a three-dimensional wound packing member unit when made by the first aspect of the present invention.
According to a sixth embodiment there is provided a kit comprising a plurality of three-dimensional wound packing member units according to the second embodiment linked together by a thread.
According to a seventh embodiment there is provided a wound packing unit comprising a resilient, fluid absorbent material contained within a porous bag member, the porous bag member being made of a material which is non-adherent to the wound.
The resilient, fluid absorbent material may be any suitable known material such as gauze, foams and the like which are known for use in wound packing.
The porous bag member may be any suitable material known to be non-adherent to a wound and especially to new growing tissue. As noted above, one of the problems of using known gauzes and foams for wound packing or filling materials is that the pore sizes of the material often leads to in-growth of granulation tissue into the pores and which may be damaged on changing a wound dressing and also causing pain to the patient. The size of surface porosity of the bag member may be such that growing tissue does not grow into the surface pores and thus does not create a mechanical connection thereto. The material from which the porous bag member may be formed may be a suitable plastics sheet or net material such as EVA, PU, PP, PE, silicone, carbomethoxy cellulose, polyacrylate, for example.
The plastics sheet may comprise nets, woven materials, non-woven fibrous sheet, foams, electrospun nano fibres, for example, from a wide variety of different materials such as those noted above, for example.
A sheet film material may be configured with a certain level of porosity by perforating the sheet with any desired pattern or form of perforations.
The wound packing unit may be made from two sheets of suitable material having substantially coterminous outer shapes, for example, and be welded together at their outer peripheries so as to contain the resilient absorbent material in the cavity so formed. The bag member may comprise two sheets of material joined at their peripheries to form a pocket therein to receive the resilient, fluid absorbing material therein.
In one embodiment the sheets from which the wound packing units are made may be circular, for example.
Certain embodiments of a wound packing unit may be used as a general, stand-alone wound filling medium in the context of a dressing used for the treatment of any type of wound. Furthermore, the wound filling unit as defined is not used in a sub-divided form by, for example, cutting into a smaller member. A particular advantage of using the wound packing units as one or more units to fill a wound without cutting as with known wound packing materials such as gauze and foam on their own is that there is no shedding of particles due to cutting and consequently no occluded particles in the wound which may lead to infection.
Whilst the wound packing unit may be used singly or in a plurality thereof as general wound filling member(s) in any dressing where suitable, certain embodiments of a wound packing unit may advantageously be used as part of a wound dressing in TNP therapy. In such a dressing, the wound packing unit or plurality of them may be used to pack the wound and, the most basic form of TNP therapy, a covering film or drape adhered over the wound to the patient's sound flesh surrounding the wound in order to form a closed or sealed cavity over the wound, and an aspirant conduit connected to a vacuum source being admitted to the so-formed wound cavity.
When used as part of a dressing in TNP therapy the sheet material may desirably be textured so as to form channels in the surface adjacent the wound surface to further enhance the generation of an even negative pressure distribution over the surface of the wound and to enhance the flow and drainage of wound exudate to an aspirant conduit so that it may be aspirated from the wound vicinity into a remotely located waste receptacle. Whilst the filling of the bag member may be an absorbent material able to absorb wound exudate, it is nevertheless beneficial that as much of the exudate as possible is aspirated to a waste receptacle. In this way risk of infection due to build up of exudate may be minimised.
In one embodiment of a porous bag member the textured surface may comprise an array of hexagonal indentations or depressions in the bag material surface effectively producing a three-dimensional surface structure, some or all of the indentations or depressions having a perforation located substantially at its centre to allow fluid flow, both gaseous and liquid, over both surfaces of the bag member, i.e. between the wound surface and bag surface and between the bag surface and filling. A suitable material from which the bag member may be made may be a vacuum formed plastics sheet material such as, for example, EVA film which is soft and non-adherent to a wound surface.
The bag member may have any desired surface topography and formations which are conducive to wound surface therapy.
When used in TNP therapy, the bag member may have an aspirant conduit having a drain portion affixed during manufacture with its drain end inside the bag member and surrounded by the resilient absorbent filling. In this way time may be saved applying a TNP dressing and also the correct positioning of the aspirant conduit may be ensured.
The resilient absorbent filling material within the bag member may also be provided with antimicrobial additives such as silver, for example, to reduce or control bacterial load so as to control infection.
The resilient absorbent material filling of the wound packing unit may also advantageously be provided with other biologically active components in addition to or in substitution of silver, such as antimicrobial compounds (e.g. silver containing species, iodine, guanidines, biguanidines etc.), analgesics (e.g. aspirin, ibuprofen etc.), anaesthetics (e.g. amethocaine, lignocaine etc.), growth factors (e.g. VEGF, PDGF), vasodilators (e.g. NO, sildenafil, histamine etc.) for example. Other examples of suitable active components may be found in WO 2005/105180 the content of which is included herein by reference.
The sheet material of certain embodiments of wound packing units may optionally be soaked or coated in a non-adherent gel such as, for example, a petroleum gel an example of which is Cuticerin™, silicone gel or a hydrogel.
As with the filling the sheet material forming the porous bag member may also be treated with silver for antimicrobial purposes etc.
The resilient, fluid absorbent material within the porous bag member or the porous bag member itself may be formed from laminated material so as to provide a texture to the wound packing member unit. Such laminated material may have a “quilted” type of texture where two layers of material may be welded together in a pre-determined pattern with a layer of a resilient material such as an open cell polymer foam, for example, between. The two outer material layers of the laminate may be provided with an array of pores in predetermined fashion to permit ingress of exudate. Some cells formed by a laminating procedure may be left unperforated so as to provide resilience by virtue of compressing the air trapped inside unperforated pockets or cells so formed.
A porous bag member may be formed from two layers of laminated material as described above. Furthermore, a wound packing unit so formed may also further comprise resilient, fluid absorbent material therebetween.
The types of sealing film drapes generally used to form the overlying wound sealing medium in TNP dressings usually have a coating of adhesive over the whole surface of the film. Therefore, it may be desirable to place a second sheet of non-adhesively coated film between the sealing film drape and the wound packing unit so that when the sealing drape is removed as the first step of a dressing change the wound packing unit is not torn from the wound with it.
According to a seventh embodiment there is provided a method for packing a wound cavity comprising the steps of; forming a wound packing unit by enclosing a resilient absorbent material within a porous bag member, the porous bag member being made of a material which is non-adherent to the wound.
According to an eighth embodiment there is provided a dressing for the application of topical negative and/or positive pressure therapy to a wound, the dressing comprising in use: an optional layer of a pressure resistant porous material adjacent a surface of a wound to be treated; a first layer of a flexible wound covering and sealing material on top of the optional pressure resistant porous material adapted, in use, to surround the wound and seal against sound tissue to form, in use, a first sealed cavity with the wound; a first conduit having a first end adapted to communicate with an interface between said optional layer of porous material and said first layer of flexible wound covering and sealing material and a second end adapted to communicate with vacuum means to establish a negative pressure, in use, between said first covering and sealing material layer and a wound surface; a resiliently compressible wound packing material on top of said first layer of covering and sealing material; a second conduit having a first end adjacent said resiliently compressible wound packing material and a second end adapted to communicate with positive or negative pressure generating means; and a second layer of flexible covering and sealing material over said resiliently compressible wound packing material to form, in use, a second sealed cavity above said first sealed cavity and said wound.
According to a ninth embodiment there is provided a method of providing a dressing including a bag member on a wound on a mammal, the method comprising the steps of: optionally placing a layer of a pressure resistant material which allows fluid transmission therethrough on a bed of the wound; placing an end of a first conduit adjacent said optional layer of pressure resistant material; adhering a first layer of a flexible, wound covering and sealing material on top of the aspirant conduit and layer of pressure resistant material such that said first layer is sealed to skin surrounding the wound and to said first conduit so as to form a first sealed cavity over said wound; placing a resiliently compressible wound packing material in the wound cavity on top of said first sealing layer material; placing an end of a second conduit adjacent said wound packing material; and, placing a second layer of a flexible, adhesive coated wound covering and sealing material over said wound packing material and an area surrounding said wound to seal thereagainst and to said second conduit so as to form a second sealed cavity over said wound.
The layer of pressure resistant material is optional since it may not be needed in the case of small wounds since the vacuum within the first sealed cavity of the dressing may be able to reach substantially all parts of the wound bed without the pressure resistant layer.
It is preferred that the first and second flexible, wound covering and sealing materials are adhesive coated, semi-permeable materials allowing the wound/dressing to breathe. Suitably such materials are thin film materials commonly available and may be made from polyurethanes, such as polyester and polyether polyurethanes, elastomeric polyether polyesters and the like, for example. Common, commercially available materials include OPSITE™ and TEGADERM™, for example. The use of semi-permeable materials is primarily to allow the wound region to breath and prevent maceration of the wound periphery.
In preferred embodiments, the dressing is effectively sealed to the skin surrounding the wound by means of the flexible, adhesive coated film material. However, the term “sealed” is not an absolute requirement nor practically attainable since many flexible dressing membrane materials forming the wound cover are composed of semi-permeable plastics materials which are well known to those skilled in the art. The term semi-permeable is defined as being permeable to water vapour and gases but not liquids and has a transmissibility of moisture vapour greater than 500 g/sq·m/per 24 hr period; if the transmission of moisture vapour is less than this figure then the material is not considered to be semi-permeable. Furthermore, there is almost inevitably some leakage between the skin to which the sealing dressing material is adhered, usually by well known pressure sensitive adhesives, due to hairs and/or other skin surface irregularities and/or imperfections which are not easily completely sealed in absolute terms. Examples of the types of self adhesive, flexible dressing drape materials which are ordinarily used in TNP type therapy as sealing membranes over and around wounds are listed hereinabove and are well known to those skilled in the art and will not be elaborated on further herein unless necessary.
A particular advantage of certain embodiments of bag dressings in comparison with conventional porous type wound packing materials is that the fluids around the wound may be rapidly aspirated away from the wound thus reducing build up of toxins and bacterial burden. Furthermore, pressure in the bag (second sealed cavity) may be changed independently of suction applied to the wound (first) cavity and tissue thus allowing for pain reduction and allowing the application of varying mechanical stress to the tissue.
The layer of pressure resistant material which allows fluid transmission therethrough placed on the wound bed is intended to both support the overlying first flexible layer of sealing material and to prevent it being drawn down into contact with the wound bed when a negative pressure (relative to atmospheric pressure) is applied via the first conduit to the first sealed cavity over the wound. Thus, the purpose of the pressure resistant layer in contact with the wound bed is to resist being crushed by the negative pressure level employed and to permit the establishment of a uniform negative pressure distribution over the whole area of the wound bed and thus render the entire wound area available and susceptible to the benefit of the reduced pressure so as to stimulate blood flow thereto and to some or all of the remaining known benefits of TNP therapy.
A further advantage is that the optional pressure resistant material which contacts the wound may be kept thin and consequently drapeable such that it is able to conform to and remain in contact with the wound surface.
The pressure resistant layer may be porous or may have surface texture or topography such as channels or indentations which allow the transfer of fluids such as aspirant fluid or wound exudate over the area of the layer. The layer of pressure resistant material may be bio-compatible and/or bio-absorbable such as collagen, oxidised cellulose, chitosan, INTEGRA™ or other suitable materials know to those skilled in the art, for example. In such materials it may be advantageous to have pores optimised for promoting the growth of tissue.
It is preferred that the pressure resistant material layer is non-adherent to raw tissue and has small pores sufficiently small to prevent tissue growth into the pores. Such materials are often referred to as “wound contact layers”. Whilst the material is referred to as pressure resistant this is only in so far as the material is required to maintain adequate porosity at the desired maximum extent of negative pressure which may be around 250 mmHg below atmospheric pressure.
The pressure resistant material may be bio-absorbable.
The first sealed cavity may also have an optional thin layer of wound packing material on top of the pressure resistant material layer. The layer of wound packing material over the wound may not be required but may be valuable in some large wounds or tunneling or fistula type wounds.
The first conduit may be a flexible plastics material tube having an array of holes therein in the wall thereof in the portion of the conduit which is contained within the dressing first sealed cavity. The first conduit is to apply a negative pressure to the wound first sealed cavity of the dressing thereby both aspirating the wound surface and inter alia stimulating blood flow thereto and also removing wound exudates from the wound site so removing materials which may be detrimental to wound healing. The first conduit may be in operable connection to apparatus having means such as vacuum pump means, for example, for applying a negative pressure.
In some embodiments, optionally one or more additional conduits may also be sealed into operable connection with the first sealed cavity, these conduits being for, for example, the supply of irrigation or cleansing fluids; pharmaceutical agents intended to have healing therapeutic effects on the wound; or to return beneficial fluids which have been removed from the wound site as exudates and mixed with other fluids and treated by, for example, a dialysis technique to the wound. Such techniques are fully discussed in the International patent applications referenced hereinabove.
Thus, the first sealed cavity provided by the first sealing layer of flexible, adhesive coated film material may render some or all of the known beneficial effects of TNP therapy and those additional known techniques mentioned hereinabove in relation to the International patent applications of common ownership herewith to the wound. The first sealed cavity provides in effect an isolated, sealed therapeutic environment for wound healing.
Before carrying out the remaining steps of the method it may be beneficial to employ an optional additional step of applying a negative pressure to the first sealed cavity in order to draw the constituent layers down towards the wound.
The resiliently compressible wound packing material is then placed on top of the first sealing layer such that, preferably, it is just above skin level and is shaped so as to conform generally to the wound shape.
One purpose of the resiliently compressible packing material is to prevent opposite edges of the wound from growing together too quickly and overgrowing the wound itself to form a closed wound cavity.
Preferably, the resiliently compressible packing material may be transparent to enable a clinician, for example, to view the wound to assess healing progress. An example of a suitable material may be a polyurethane based plastics foam material.
The resiliently compressible wound filler may be any suitable porous material such as foam, mesh material, knitted material, corrugated material, for example, and relatively very large pore sizes up to about 10 mm may be employed. Larger pore sizes may be used but there is a limit imposed where the adhesive film may be pulled into the pores by negative pressure effect and may stick to the porous material. However, this latter problem may be overcome by interposing a sheet of a suitable material between the resiliently compressible wound packing material and the second flexible wound covering and sealing material. Suitable materials may include polyethylene and polyvinyl acetate, for example.
The second conduit may be placed adjacent the resiliently compressible wound packing material and the second layer of flexible, adhesive coated sealing material put in place to create the second sealed cavity. The second sealed cavity is isolated from the wound and is present to work or stress the wound tissue for its beneficial effect thereon. The second conduit may be connected to suitable pump means to apply a positive pressure (relative to atmospheric) and/or a negative pressure to the second sealed cavity. In most of the prior art which shows bag members or bladders, they are employed to work or stress the tissue in the wound region by inflation thereof and cycling and/or pulsing, for example, of the pressure within the bladder in a number of different ways. However, none of the bladders shown in the prior art possess the resiliently compressible wound filler illustrated in certain embodiments. Thus the wound being treated by the dressing may be worked or stressed by providing a positive pressure in the second sealed cavity and/or a negative pressure therein. When a negative pressure is applied the effect is that ambient atmospheric pressure serves to compress the resiliently compressible wound filler material which itself, being resilient provides a positive force on the wound bed and surrounding tissue due to its compression and being held against the wound by ambient atmospheric pressure. In the dressing according to a certain embodiment, the ambient atmosphere is not applied to the underside of the second sealed cavity as this space is occupied by the first sealed cavity which itself is sealed from ambient atmospheric pressure on the wound side thus, the stresses acting to expand the wound filler material when compressed act in a downwardly direction against the wound region. The forces provided by the compressed wound filler on the wound may be controlled by, for example, the degree of porosity, pore size, the material from which it is composed and the level of positive or negative pressure applied to the second sealed cavity. Thus, embodiments of the dressing are able to work or stress the wound over a much greater range of conditions. The range of pressures over which the second sealed cavity may be used is from +300 mmHg to −400 mmHg. Typical pressures may lie in the range from about +50 to −200 mmHg, more preferably from +25 mmHg to −150 mm. Inclusion of the compressible filler gives greater range and control particularly for contraction of the wound.
The resiliently compressible wound filling material may be a foam formed in situ in the wound according to patent application, PCT/GB2008/050268, the entire contents of which are incorporated herein by reference.
The fluid used to apply pressure to the second sealed cavity is preferably a gas such as air, for example, but could be a liquid such as water. However, a gas is preferred owing to its compressible nature in case a patient rolls on top of the dressing causing discomfort. The fluid may be pressure pulsed to “work” the tissue surface.
The fluid used to apply pressure may be temperature controlled.
The second layer of flexible, adhesive coated sealing material which finally seals the wound and second cavity may be formed from a stronger film material or a reinforced material so as to resist upwardly directed stresses which put the material under tension, which may cause “ballooning” when the second cavity is inflated with a positive pressure, for example.
Additional conduits may be placed in the first and/or second sealed cavities in order to monitor the pressures therein and/or to supply medication thereto.
A particular advantage of some embodiments of methods of making a dressing is that some or all of the component parts thereof may be tailored to fit the wound under consideration and that no compromises are required thus providing improved wound therapy.
The first and second conduits may be combined into a single, multi-lumen conduit. In this case the first covering and sealing layer may be provided with a port member which accepts the multi-lumen conduit and the fluid flow paths in the multi-lumen conduit being directed as appropriate by the port into the respective first and second sealed cavities.
Such port members may also allow the pressure, negative or positive, in the first and/or second sealed cavities to be monitored and/or controlled by means of additional lumens connected to control/monitoring devices remote from the wound. Such devices may comprise the vacuum/pressure generating means and transducer means, for example, to monitor the pressure at the wound. Such transducer means may be further linked to control means to control the pressure/vacuum generating means and/or valve/air bleed means into the first and/or second sealed cavities.
According to a tenth embodiment there is provided a port member for a dressing, the port member comprising a body portion having flow passages adapted to co-operate with at least two lumens; a face portion adapted to be adhered to a flexible membrane material; and, the flow passages being directed on either side of said face portion.
The port member has at least one fluid flow passage configured to communicate with a region on a first side of the face portion.
The port member has at least one fluid flow passage configured to communicate with a region on a second side of the face portion.
A suitable port member may be molded from a soft plastics material such as polyurethane, silicone or polypropylene, for example, and comprises a base flange face portion having an adhesive layer on at least a peripheral portion of the base flange to allow the port member to be adhered or welded to the first flexible covering and sealing material layer of the dressing. The port member may have at least two fluid flow passages therein adapted to co-operate with first and second conduit lumens. When the port member is adhered to the first flexible covering and sealing material the fluid flow passages in the port member permit fluid flow on each side of the first flexible covering and sealing material film. Thus, one lumen in the conduit is able to apply a negative pressure to the first sealed cavity and the second lumen is able to apply either a negative pressure or a positive pressure to the second sealed cavity as appropriate.
The adhesive layer of the base flange face portion may be protected before use with a known peelable and discardable paper such as siliconised paper for example, prior to adhering the port member to a dressing covering and sealing material.
According to a twelfth embodiment there is provided a kit for the provision of a topical negative pressure therapy dressing for a wound, the kit comprising: pressure resistant porous material for placement, in use, adjacent a wound surface; flexible covering and sealing material adapted, in use, for adhering to sound skin; resiliently compressible porous wound packing material; a conduit comprising at least two lumens; and, a port member having at least two flow passages adapted to co-operate with said two lumens.
Referring now to the drawings and where the same features are denoted by common reference numerals,
With regard to the dressing 32 and grommet 38 reference is made to GB patent application 0712735.0 and PCT/US 2007/074374 of common ownership herewith, the contents of which are included herein by reference, and which explain in detail the structure and constitution of these features but which are relatively incidental to the present application and could be replaced with any suitable means of sealing the conduit 18 to the sealing drape 46 to prevent ingress of ambient air into the wound cavity from this particular source.
The wound filling device 12 comprises an inflatable bag member 14 having an outer covering sock member 16. The inflatable bag member 14 may be made in certain embodiments by welding two circular sheets 70, 72 of thin, flexible, impermeable plastics material together around their peripheries to form a weld bead 74. The upper sheet 70 has a central circular aperture 76 therein of a size suitable to be affixed to a thin flange 78 around the periphery 80 of the port member 38, the flange 78 and aperture 76 edge being either welded together or adhesively bonded so as to make the inflatable bag member 14 and the port member 38 an integral item.
The sock member 16 may be manufactured from a thin flexible plastics material such as EVA, for example and which has a vacuum-formed textured surface 80. The surface topography comprises an array of hexagonal indentations 82. Some or all of the indentations 82 may have a central perforation 84. The individual hexagons are separated by channels 86 as shown in
In this embodiment, the sock member may have a textured surface over substantially the whole area thereof, the surface being configured to maintain a continuous flow path for aspirated fluid to the port member 38 as described below.
Although the example of the wound filling device described above is stated to be made with circular sheets of material, it is of course merely exemplary and the inflatable bag 14 and sock member 16 may be made of any suitable shape and size to suit a particular wound shape and size or a range of wound shapes and sizes.
The port member 38 may be moulded from a soft and conformable EVA material, for example, such that if lain upon by a patient no resulting trauma is caused by use of a hard material. The port member 38 comprises a main body portion 100 having passages for connection to lumens 20(52), 22(54), 24(56) in conduit 18 and the flange portion 78 which may be welded to the periphery of aperture 76 of the inflatable bag member around the periphery 80 of the main body portion 100. The port member has a socket portion 102 corresponding to and co-operating with the outer shape of the conduit 18 such that the conduit may be plugged directly into the socket 102 and which effects simultaneous connections with the individual limens 20, 22, 24 therein. Lumen 22 connects with passage 104 which passes through the upper part of the main body portion 100 to communicate with the wound cavity 40 (see
The body portion 100 of the port member 38 may have a flanged face portion 78 extending therearound, the lower face of which may be provided with an adhesive layer to enable the port member 38 to be adhered to the sealing drape 46. Before use the adhesive layer may be protected with a siliconised paper layer (not shown) in a known manner. When adhered to the sealing drape 46, the fluid flow passage 106 communicates with the sealing drape 46 through an aperture made in the sealing drape 46 (not shown) and to aspirate fluid inclusive of wound exudate from that cavity and provided a vacuum thereto. The port member described above has three fluid flow passages therethrough, however, the port member may has two passages or even more than three passages and may be tailored to provide other functions in additions to those described.
In this embodiment, the wound filling device 612 comprises a sealed bag member 630 being filed with polystyrene beads of a size range 0.1 to 20 mm preferably 1.0 to 10.0 mm. In some embodiments, the bag material may be embossed (not shown) EVA sheet, cut to size and welded at a seam (not shown) after filling with the beads. In operation and since the bag member 630 is not porous or otherwise permeable, wound exudate may be drawn around the outer surface of the bag member towards the drains conduit portion 616 from whence it is aspirated away from the wound site through the conduit 620 in known manner. Due to the vacuum produced by the pump 622 and the surrounding ambient atmospheric pressure, the wound filling device 612 may be pressed into intimate contact with the wound surface, however, an even vacuum depression may be achieved over the whole wound surface due to the embossed surface texture of the EVA material and the contained polystyrene beads providing a multitude of channels along which exudate may be aspirated. Thus, the interior of the wound filling device 612 and the contained beads do not become filled or saturated with wound exudate and which lessens the bacterial load at the wound 10 thus also lessening the risk of infection.
The wound filling devices in
Alternatively, in some circumstances it may be beneficial for the fluid 1026 to be cooled rather than heated and the apparatus described above contemplates cooling rather than heating of the fluid 326.
The bag member 1004 may be provided with a stub conduit sealed by a clamp and a separate conduit appropriate to the associated apparatus layout described above attached to the stub by known means.
Further embodiments of wound filling devices may include three-dimensional wound packing members, and certain embodiments may comprise a plurality of such wound packing members linked together.
The wound packing unit described above with respect to
The embodiment 1700 shown in
Both the embodiments of
Referring now to
Referring now to
As will be seen from the above two embodiments, it is possible to provide a dressing to both aspirate a wound by TNP therapy giving some or all of the benefits associated therewith by the first sealed cavity and also simultaneously to work or stress a wound to provide benefits associated with that therapeutic technique in one dressing by pressure pulsing or cycling through positive and negative pressures by the second sealed cavity.
As will be appreciated from the above, complex dressings can be made from component parts held in most hospitals.
Further embodiments can be seen in the following paragraphs:
While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the device or process illustrated may be made without departing from the spirit of the disclosure. Additionally, the various features and processes described above may be used independently of one another, or may be combined in various ways. It will be clear to a person skilled in the art that features described in relation to any of the embodiments described above can be applicable interchangeably between the different embodiments. All possible combinations and subcombinations are intended to fall within the scope of this disclosure. Many of the embodiments described above include similar components, and as such, these similar components can be interchanged in different embodiments.
For example the unitary conduit 18 may be changed for separate conduits and an appropriate grommet member 28 or the grommet may be dispensed with and the conduits sealed to the overlying drape as is known in the TNP art. Similarly, the port member may be adapted to co-operate with separate conduits and a shroud member appropriately modified so as to be able to aspirate the wound cavity without hindrance. The form of the texturing of the sock surface and the material of which it is made may be varied insofar as the sock does not cause unnecessary trauma to the wound and is able to maintain an even pressure distribution over the whole of the wound surface area. These and many other modifications may be made without departing from the scope or spirit of the present application.
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0723852 | Dec 2007 | GB | national |
| 0723874 | Dec 2007 | GB | national |
| 0724039 | Dec 2007 | GB | national |
| 0724040 | Dec 2007 | GB | national |
| 0724044 | Dec 2007 | GB | national |
This application is a continuation of U.S. application Ser. No. 16/115,064, filed Aug. 28, 2018, which is a continuation of U.S. application Ser. No. 14/855,214, filed Sep. 15, 2015, which is a divisional of U.S. application Ser. No. 13/545,942, filed Jul. 10, 2012, which is a continuation-in-part of U.S. application Ser. No. 12/746,504, filed Jun. 4, 2010, which is a U.S. National Phase of PCT International Application No. PCT/GB2008/051114, filed on Nov. 26, 2008, designating the United States and published on Jun. 11, 2009 as WO 2009/071932, which claims priority to Great Britain Patent Application No. 0723874.4, filed Dec. 6, 2007. This application is also a continuation-in-part of U.S. application Ser. No. 12/746,508, filed Jun. 4, 2010, which is a U.S. National Phase of PCT International Application No. PCT/GB2008/051122, filed on Nov. 26, 2008, designating the United States and published on Jun. 11, 2009 as WO 2009/071935, which claims priority to Great Britain Patent Application No. 0723852.0, filed Dec. 6, 2007. This application is also a continuation-in-part of U.S. application Ser. No. 12/746,757, filed Jun. 7, 2010, which is a U.S. National Phase of PCT International Application No. PCT/GB2008/051075, filed on Nov. 17, 2008, designating the United States and published on Jun. 11, 2009 as WO 2009/071929, which claims priority to Great Britain Patent Application No. 0724044.3, filed Dec. 8, 2007. This application is also a continuation-in-part of U.S. application Ser. No. 12/746,753, filed Jun. 7, 2010, which is a U.S. National Phase of PCT International Application No. PCT/GB2008/051134, filed on Nov. 28, 2008, designating the United States and published on Jun. 11, 2009 as WO 2009/071938, which claims priority to Great Britain Patent Application No. 0724040.1, filed Dec. 8, 2007. This application is also a continuation-in-part of U.S. application Ser. No. 12/746,751, filed Jun. 7, 2010, which is a U.S. National Phase of PCT International Application No. PCT/GB2008/051070, filed on Nov. 17, 2008, designating the United States and published on Jun. 11, 2009 as WO 2009/071928, which claims priority to Great Britain Patent Application No. 0724039.3, filed Dec. 8, 2007. The disclosures of these prior applications are hereby incorporated by reference in their entireties and should be considered a part of this specification.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1400124 | Wolverton et al. | Dec 1921 | A |
| 3276472 | Jinkens et al. | Oct 1966 | A |
| 3367332 | Groves | Feb 1968 | A |
| 3750704 | Burke et al. | Aug 1973 | A |
| 3837922 | Ng et al. | Sep 1974 | A |
| 4117551 | Brooks et al. | Sep 1978 | A |
| 4468219 | George et al. | Aug 1984 | A |
| 4538920 | Drake | Sep 1985 | A |
| 4573965 | Russo | Mar 1986 | A |
| 4664662 | Webster | May 1987 | A |
| 4753536 | Spehar et al. | Jun 1988 | A |
| 4759354 | Quarfoot | Jul 1988 | A |
| 4767026 | Keller et al. | Aug 1988 | A |
| 4771919 | Ernst | Sep 1988 | A |
| 4872450 | Austad | Oct 1989 | A |
| 4969880 | Zamierowski | Nov 1990 | A |
| 5010115 | Grisoni | Apr 1991 | A |
| 5064652 | Bay | Nov 1991 | A |
| 5064653 | Sessions et al. | Nov 1991 | A |
| 5073172 | Fell | Dec 1991 | A |
| 5080493 | McKown et al. | Jan 1992 | A |
| 5176663 | Svedman et al. | Jan 1993 | A |
| 5207641 | Allton | May 1993 | A |
| 5249709 | Duckworth et al. | Oct 1993 | A |
| 5266326 | Barry et al. | Nov 1993 | A |
| 5320599 | Griep et al. | Jun 1994 | A |
| 5333760 | Simmen | Aug 1994 | A |
| 5336171 | Sugarbaker | Aug 1994 | A |
| 5370610 | Reynolds | Dec 1994 | A |
| 5437651 | Todd et al. | Aug 1995 | A |
| 5456745 | Roreger et al. | Oct 1995 | A |
| 5470625 | Perrault | Nov 1995 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5549585 | Maher et al. | Aug 1996 | A |
| 5582596 | Fukunaga et al. | Dec 1996 | A |
| 5583114 | Barrows et al. | Dec 1996 | A |
| 5609271 | Keller et al. | Mar 1997 | A |
| 5612050 | Rowe et al. | Mar 1997 | A |
| 5630855 | Lundb ack | May 1997 | A |
| 5633007 | Webb | May 1997 | A |
| 5636643 | Argenta | Jun 1997 | A |
| 5645081 | Argenta | Jul 1997 | A |
| 5660823 | Chakrabarti et al. | Aug 1997 | A |
| 5717030 | Dunn et al. | Feb 1998 | A |
| 5747064 | Burnett et al. | May 1998 | A |
| 5760754 | Amero, Jr. et al. | Jun 1998 | A |
| 5776193 | Kwan et al. | Jul 1998 | A |
| 5786682 | Aiken et al. | Jul 1998 | A |
| 5788667 | Stoller | Aug 1998 | A |
| 5833642 | McCabe et al. | Nov 1998 | A |
| 5834007 | Kubota | Nov 1998 | A |
| 5874500 | Rhee et al. | Feb 1999 | A |
| 5945115 | Dunn et al. | Aug 1999 | A |
| 5962010 | Greff et al. | Oct 1999 | A |
| 5988842 | Johnsen et al. | Nov 1999 | A |
| 5998472 | Berger et al. | Dec 1999 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6129440 | Reynolds | Oct 2000 | A |
| 6135116 | Vogel et al. | Oct 2000 | A |
| 6143352 | Clark et al. | Nov 2000 | A |
| 6165201 | Sawhney et al. | Dec 2000 | A |
| 6168788 | Wortham | Jan 2001 | B1 |
| 6214332 | Askill et al. | Apr 2001 | B1 |
| 6229286 | Tokuyama | May 2001 | B1 |
| 6252129 | Coffee | Jun 2001 | B1 |
| 6345623 | Heaton et al. | Feb 2002 | B1 |
| 6391294 | Dettmar et al. | May 2002 | B1 |
| 6398761 | Bills et al. | Jun 2002 | B1 |
| 6398767 | Fleischmann | Jun 2002 | B1 |
| 6447802 | Sessions et al. | Sep 2002 | B2 |
| 6458109 | Henley | Oct 2002 | B1 |
| 6486285 | Fujita | Nov 2002 | B2 |
| 6495127 | Wallace et al. | Dec 2002 | B1 |
| 6509031 | Miller et al. | Jan 2003 | B1 |
| 6521251 | Askill et al. | Feb 2003 | B2 |
| 6547467 | Quintero | Apr 2003 | B2 |
| 6553998 | Heaton et al. | Apr 2003 | B2 |
| 6575940 | Levinson et al. | Jun 2003 | B1 |
| 6596704 | Court et al. | Jul 2003 | B1 |
| 6627216 | Brandt et al. | Sep 2003 | B2 |
| 6629774 | Gruendeman | Oct 2003 | B1 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6692132 | Meeker | Feb 2004 | B1 |
| 6695823 | Lina et al. | Feb 2004 | B1 |
| 6730299 | Tayot et al. | May 2004 | B1 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6767334 | Randolph | Jul 2004 | B1 |
| 6790438 | Constancis et al. | Sep 2004 | B1 |
| 6814079 | Heaton et al. | Nov 2004 | B2 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6903243 | Burton | Jun 2005 | B1 |
| 6936037 | Bubb et al. | Aug 2005 | B2 |
| 6951553 | Bubb et al. | Oct 2005 | B2 |
| 6979324 | Bybordi | Dec 2005 | B2 |
| 7025742 | Rubenstein et al. | Apr 2006 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7077832 | Fleischmann | Jul 2006 | B2 |
| 7108683 | Zamierowski | Sep 2006 | B2 |
| 7117869 | Heaton et al. | Oct 2006 | B2 |
| 7128735 | Weston | Oct 2006 | B2 |
| 7129210 | Lowinger et al. | Oct 2006 | B2 |
| 7195624 | Lockwood et al. | Mar 2007 | B2 |
| 7214202 | Vogel et al. | May 2007 | B1 |
| 7216651 | Argenta et al. | May 2007 | B2 |
| 7279612 | Heaton et al. | Oct 2007 | B1 |
| 7303757 | Schankereli et al. | Dec 2007 | B2 |
| 7381859 | Hunt et al. | Jun 2008 | B2 |
| 7520872 | Biggie | Apr 2009 | B2 |
| 7524315 | Blott | Apr 2009 | B2 |
| 7534927 | Lockwood et al. | May 2009 | B2 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7615036 | Joshi et al. | Nov 2009 | B2 |
| 7625362 | Boehringer et al. | Dec 2009 | B2 |
| 7699823 | Haggstrom et al. | Apr 2010 | B2 |
| 7700819 | Ambrosio et al. | Apr 2010 | B2 |
| 7708724 | Weston | May 2010 | B2 |
| 7717313 | Criscuolo et al. | May 2010 | B2 |
| 7722582 | Lina et al. | May 2010 | B2 |
| 7745681 | Ferguson | Jun 2010 | B1 |
| 7753894 | Blott et al. | Jul 2010 | B2 |
| 7754937 | Boehringer et al. | Jul 2010 | B2 |
| 7758554 | Lina et al. | Jul 2010 | B2 |
| 7759537 | Bishop et al. | Jul 2010 | B2 |
| 7759538 | Fleischmann | Jul 2010 | B2 |
| 7759539 | Shaw et al. | Jul 2010 | B2 |
| 7763769 | Johnson et al. | Jul 2010 | B2 |
| 7775998 | Riesinger | Aug 2010 | B2 |
| 7779625 | Joshi et al. | Aug 2010 | B2 |
| 7790945 | Watson, Jr. | Sep 2010 | B1 |
| 7790946 | Mulligan | Sep 2010 | B2 |
| 7803980 | Griffiths et al. | Sep 2010 | B2 |
| 7811269 | Boynton et al. | Oct 2010 | B2 |
| 7815616 | Boehringer et al. | Oct 2010 | B2 |
| 7828782 | Suzuki | Nov 2010 | B2 |
| 7838717 | Haggstrom et al. | Nov 2010 | B2 |
| 7846141 | Weston | Dec 2010 | B2 |
| 7862831 | Wang et al. | Jan 2011 | B2 |
| 7880050 | Robinson et al. | Feb 2011 | B2 |
| 7896823 | Mangrum et al. | Mar 2011 | B2 |
| 7909805 | Weston | Mar 2011 | B2 |
| 7910135 | St. John et al. | Mar 2011 | B2 |
| 7922703 | Riesinger | Apr 2011 | B2 |
| 7964766 | Blott et al. | Jun 2011 | B2 |
| 8007164 | Miyano et al. | Aug 2011 | B2 |
| 8012169 | Joshi | Sep 2011 | B2 |
| 8034038 | Biggie | Oct 2011 | B2 |
| 8062272 | Weston | Nov 2011 | B2 |
| 8062273 | Weston | Nov 2011 | B2 |
| 8080702 | Blott et al. | Dec 2011 | B2 |
| 8092441 | Sugito | Jan 2012 | B2 |
| 8097272 | Addison | Jan 2012 | B2 |
| 8118794 | Weston | Feb 2012 | B2 |
| 8119160 | Looney et al. | Feb 2012 | B2 |
| 8133211 | Cavanaugh, II et al. | Mar 2012 | B2 |
| 8158844 | McNeil | Apr 2012 | B2 |
| 8162907 | Heagle | Apr 2012 | B2 |
| 8192409 | Hardman et al. | Jun 2012 | B2 |
| 8226942 | Charier et al. | Jul 2012 | B2 |
| 8241261 | Randolph et al. | Aug 2012 | B2 |
| 8267908 | Coulthard | Sep 2012 | B2 |
| 8273368 | Ambrosio et al. | Sep 2012 | B2 |
| 8282611 | Weston | Oct 2012 | B2 |
| 8303552 | Weston | Nov 2012 | B2 |
| 8372049 | Jaeb et al. | Feb 2013 | B2 |
| 8372050 | Jaeb et al. | Feb 2013 | B2 |
| 8382731 | Johannison | Feb 2013 | B2 |
| 8398614 | Blott et al. | Mar 2013 | B2 |
| 8409157 | Haggstrom et al. | Apr 2013 | B2 |
| 8410189 | Carnahan et al. | Apr 2013 | B2 |
| 8460255 | Joshi et al. | Jun 2013 | B2 |
| 8535296 | Blott et al. | Sep 2013 | B2 |
| 8545464 | Weston | Oct 2013 | B2 |
| 8569566 | Blott et al. | Oct 2013 | B2 |
| 8628505 | Weston | Jan 2014 | B2 |
| 8753670 | Delmotte | Jun 2014 | B2 |
| 8795243 | Weston | Aug 2014 | B2 |
| 8795247 | Bennett et al. | Aug 2014 | B2 |
| 8795635 | Tamarkin et al. | Aug 2014 | B2 |
| 8795713 | Makower et al. | Aug 2014 | B2 |
| 8801685 | Armstrong | Aug 2014 | B2 |
| 8834451 | Blott et al. | Sep 2014 | B2 |
| 8843327 | Vernon-Harcourt et al. | Sep 2014 | B2 |
| 8961496 | Locke et al. | Feb 2015 | B2 |
| 8968773 | Thomas et al. | Mar 2015 | B2 |
| 9028872 | Gaserod et al. | May 2015 | B2 |
| 9205001 | Blott et al. | Dec 2015 | B2 |
| 9387126 | Blott et al. | Jul 2016 | B2 |
| 9446178 | Blott et al. | Sep 2016 | B2 |
| 9452244 | Blott et al. | Sep 2016 | B2 |
| 9452248 | Blott et al. | Sep 2016 | B2 |
| 9456928 | Haggstrom et al. | Oct 2016 | B2 |
| 9526817 | Blott et al. | Dec 2016 | B2 |
| 10080689 | Hall et al. | Sep 2018 | B2 |
| 20010004082 | Keller et al. | Jun 2001 | A1 |
| 20010029956 | Argenta | Oct 2001 | A1 |
| 20010031943 | Urie | Oct 2001 | A1 |
| 20010043913 | Spaans et al. | Nov 2001 | A1 |
| 20010043943 | Coffey | Nov 2001 | A1 |
| 20020016577 | Ohmstede | Feb 2002 | A1 |
| 20020019367 | Vournakis et al. | Feb 2002 | A1 |
| 20020038826 | Hurray et al. | Apr 2002 | A1 |
| 20020065494 | Lockwood et al. | May 2002 | A1 |
| 20020122771 | Holland et al. | Sep 2002 | A1 |
| 20020145007 | Sawhney et al. | Oct 2002 | A1 |
| 20020187182 | Kramer et al. | Dec 2002 | A1 |
| 20020193721 | Vandruff | Dec 2002 | A1 |
| 20020198490 | Wirt et al. | Dec 2002 | A1 |
| 20020198503 | Risk, Jr. et al. | Dec 2002 | A1 |
| 20020198504 | Risk, Jr. et al. | Dec 2002 | A1 |
| 20030040478 | Drucker et al. | Feb 2003 | A1 |
| 20030040687 | Boynton et al. | Feb 2003 | A1 |
| 20030050594 | Zamierowski | Mar 2003 | A1 |
| 20030069535 | Shalaby | Apr 2003 | A1 |
| 20030097100 | Watson | May 2003 | A1 |
| 20030143189 | Askill et al. | Jul 2003 | A1 |
| 20030183653 | Bills | Oct 2003 | A1 |
| 20030208149 | Coffey | Nov 2003 | A1 |
| 20030212357 | Pace | Nov 2003 | A1 |
| 20030212359 | Butler | Nov 2003 | A1 |
| 20040006319 | Lina et al. | Jan 2004 | A1 |
| 20040030304 | Hunt et al. | Feb 2004 | A1 |
| 20040033466 | Shellard et al. | Feb 2004 | A1 |
| 20040037897 | Benjamin et al. | Feb 2004 | A1 |
| 20040049187 | Burnett et al. | Mar 2004 | A1 |
| 20040054338 | Bybordi | Mar 2004 | A1 |
| 20040064132 | Boehringer et al. | Apr 2004 | A1 |
| 20040073152 | Karason et al. | Apr 2004 | A1 |
| 20040087739 | Onder | May 2004 | A1 |
| 20040167617 | Voellmicke et al. | Aug 2004 | A1 |
| 20040171998 | Marasco, Jr. | Sep 2004 | A1 |
| 20050029976 | Terry et al. | Feb 2005 | A1 |
| 20050065484 | Watson, Jr. | Mar 2005 | A1 |
| 20050082435 | Rasmussen et al. | Apr 2005 | A1 |
| 20050085795 | Lockwood et al. | Apr 2005 | A1 |
| 20050090787 | Risk, Jr. et al. | Apr 2005 | A1 |
| 20050131327 | Lockwood et al. | Jun 2005 | A1 |
| 20050137539 | Biggie | Jun 2005 | A1 |
| 20050148913 | Weston | Jul 2005 | A1 |
| 20050196450 | Touitou | Sep 2005 | A1 |
| 20050222544 | Weston | Oct 2005 | A1 |
| 20050230422 | Muller et al. | Oct 2005 | A1 |
| 20050244484 | Flick | Nov 2005 | A1 |
| 20050261642 | Weston | Nov 2005 | A1 |
| 20050261643 | Bybordi | Nov 2005 | A1 |
| 20060009744 | Erdman et al. | Jan 2006 | A1 |
| 20060039742 | Cable, Jr. et al. | Feb 2006 | A1 |
| 20060079599 | Arthur | Apr 2006 | A1 |
| 20060100586 | Karpowicz et al. | May 2006 | A1 |
| 20060100594 | Adams et al. | May 2006 | A1 |
| 20060155260 | Blott | Jul 2006 | A1 |
| 20060173514 | Biel et al. | Aug 2006 | A1 |
| 20060177490 | Massouda | Aug 2006 | A1 |
| 20060213527 | Argenta | Sep 2006 | A1 |
| 20060253082 | McIntosh et al. | Nov 2006 | A1 |
| 20060273109 | Keller | Dec 2006 | A1 |
| 20060282028 | Howard et al. | Dec 2006 | A1 |
| 20070004896 | Ito et al. | Jan 2007 | A1 |
| 20070009580 | DiCosmo et al. | Jan 2007 | A1 |
| 20070027414 | Hoffman et al. | Feb 2007 | A1 |
| 20070032754 | Walsh | Feb 2007 | A1 |
| 20070032755 | Walsh | Feb 2007 | A1 |
| 20070032762 | Vogel | Feb 2007 | A1 |
| 20070032763 | Vogel | Feb 2007 | A1 |
| 20070032778 | Heaton et al. | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070066945 | Martin | Mar 2007 | A1 |
| 20070066946 | Haggstrom et al. | Mar 2007 | A1 |
| 20070118096 | Smith et al. | May 2007 | A1 |
| 20070129707 | Blott et al. | Jun 2007 | A1 |
| 20070131573 | Boyles | Jun 2007 | A1 |
| 20070141101 | Nugent et al. | Jun 2007 | A1 |
| 20070141128 | Blott et al. | Jun 2007 | A1 |
| 20070147947 | Stenton et al. | Jun 2007 | A1 |
| 20070156104 | Lockwood et al. | Jul 2007 | A1 |
| 20070164047 | Reidt et al. | Jul 2007 | A1 |
| 20070167926 | Blott et al. | Jul 2007 | A1 |
| 20070167927 | Hunt et al. | Jul 2007 | A1 |
| 20070185426 | Ambrosio et al. | Aug 2007 | A1 |
| 20070185463 | Mulligan | Aug 2007 | A1 |
| 20070203062 | Ellis-Behnke et al. | Aug 2007 | A1 |
| 20070219512 | Heaton | Sep 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070265585 | Joshi et al. | Nov 2007 | A1 |
| 20070265586 | Joshi et al. | Nov 2007 | A1 |
| 20070276195 | Xu et al. | Nov 2007 | A1 |
| 20070276309 | Xu et al. | Nov 2007 | A1 |
| 20070293830 | Martin | Dec 2007 | A1 |
| 20080004549 | Anderson et al. | Jan 2008 | A1 |
| 20080060550 | Macdonald et al. | Mar 2008 | A1 |
| 20080071216 | Locke et al. | Mar 2008 | A1 |
| 20080077091 | Mulligan | Mar 2008 | A1 |
| 20080082059 | Fink et al. | Apr 2008 | A1 |
| 20080089173 | Lu et al. | Apr 2008 | A1 |
| 20080119802 | Riesinger | May 2008 | A1 |
| 20080167593 | Fleischmann | Jul 2008 | A1 |
| 20080171958 | Gundersen | Jul 2008 | A1 |
| 20080200857 | Lawhorn | Aug 2008 | A1 |
| 20080200906 | Sanders et al. | Aug 2008 | A1 |
| 20080206155 | Tamarkin et al. | Aug 2008 | A1 |
| 20080208147 | Argenta et al. | Aug 2008 | A1 |
| 20080208163 | Wilkie | Aug 2008 | A1 |
| 20080223378 | Henderson et al. | Sep 2008 | A1 |
| 20080234641 | Locke et al. | Sep 2008 | A1 |
| 20080243096 | Svedman | Oct 2008 | A1 |
| 20080254103 | Harris et al. | Oct 2008 | A1 |
| 20080287880 | Keller | Nov 2008 | A1 |
| 20080294127 | Blott et al. | Nov 2008 | A1 |
| 20080294147 | Radl et al. | Nov 2008 | A1 |
| 20080300555 | Olson et al. | Dec 2008 | A1 |
| 20080314929 | Keller | Dec 2008 | A1 |
| 20090020561 | Keller | Jan 2009 | A1 |
| 20090022779 | Kelly et al. | Jan 2009 | A1 |
| 20090030086 | Eady et al. | Jan 2009 | A1 |
| 20090093550 | Rolfes et al. | Apr 2009 | A1 |
| 20090098073 | Macdonald et al. | Apr 2009 | A1 |
| 20090134186 | Keller | May 2009 | A1 |
| 20090157017 | Ambrosio | Jun 2009 | A1 |
| 20090196844 | Choi et al. | Aug 2009 | A1 |
| 20090204085 | Biggie | Aug 2009 | A1 |
| 20090216170 | Robinson et al. | Aug 2009 | A1 |
| 20090227969 | Jaeb et al. | Sep 2009 | A1 |
| 20090234306 | Vitaris | Sep 2009 | A1 |
| 20090234309 | Vitaris et al. | Sep 2009 | A1 |
| 20090240185 | Jaeb et al. | Sep 2009 | A1 |
| 20090275872 | Addison et al. | Nov 2009 | A1 |
| 20090299251 | Buan | Dec 2009 | A1 |
| 20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
| 20090299306 | Buan | Dec 2009 | A1 |
| 20100022972 | Lina et al. | Jan 2010 | A1 |
| 20100030132 | Niezgoda et al. | Feb 2010 | A1 |
| 20100036305 | Green | Feb 2010 | A1 |
| 20100069858 | Olson | Mar 2010 | A1 |
| 20100122417 | Vrzalik et al. | May 2010 | A1 |
| 20100125258 | Coulthard et al. | May 2010 | A1 |
| 20100185163 | Heagle | Jul 2010 | A1 |
| 20100210986 | Sanders et al. | Aug 2010 | A1 |
| 20100230467 | Criscuolo et al. | Sep 2010 | A1 |
| 20100262090 | Riesinger | Oct 2010 | A1 |
| 20100262091 | Larsson | Oct 2010 | A1 |
| 20100262092 | Hartwell | Oct 2010 | A1 |
| 20100262096 | Hall | Oct 2010 | A1 |
| 20100262106 | Hartwell | Oct 2010 | A1 |
| 20100268176 | Johnson et al. | Oct 2010 | A1 |
| 20100268177 | Hall | Oct 2010 | A1 |
| 20100268198 | Buan et al. | Oct 2010 | A1 |
| 20100280469 | Hall | Nov 2010 | A1 |
| 20100305526 | Robinson et al. | Dec 2010 | A1 |
| 20100324510 | Andresen et al. | Dec 2010 | A1 |
| 20110004172 | Eckstein et al. | Jan 2011 | A1 |
| 20110021431 | Jones et al. | Jan 2011 | A1 |
| 20110028918 | Hartwell | Feb 2011 | A1 |
| 20110028919 | Johnnison et al. | Feb 2011 | A1 |
| 20110028920 | Johannison | Feb 2011 | A1 |
| 20110033503 | Sinko et al. | Feb 2011 | A1 |
| 20110054421 | Hartwell | Mar 2011 | A1 |
| 20110054423 | Blott et al. | Mar 2011 | A1 |
| 20110086077 | McCrea et al. | Apr 2011 | A1 |
| 20110118683 | Weston | May 2011 | A1 |
| 20110172615 | Greener | Jul 2011 | A2 |
| 20110172617 | Riesinger | Jul 2011 | A1 |
| 20110224631 | Simmons et al. | Sep 2011 | A1 |
| 20110282309 | Adie et al. | Nov 2011 | A1 |
| 20120004631 | Hartwell | Jan 2012 | A9 |
| 20120041399 | Blott et al. | Feb 2012 | A1 |
| 20120053538 | Blott et al. | Mar 2012 | A1 |
| 20120095380 | Gergely et al. | Apr 2012 | A1 |
| 20120109085 | McNeil | May 2012 | A1 |
| 20120116334 | Albert | May 2012 | A1 |
| 20120130332 | Cotton et al. | May 2012 | A1 |
| 20130090616 | Neubauer | Apr 2013 | A1 |
| 20130096518 | Hall | Apr 2013 | A1 |
| 20130116635 | Fleischmann | May 2013 | A1 |
| 20130123723 | Tout et al. | May 2013 | A1 |
| 20130138054 | Fleischmann | May 2013 | A1 |
| 20130144230 | Wu et al. | Jun 2013 | A1 |
| 20130150814 | Buan | Jun 2013 | A1 |
| 20130165878 | Heagle | Jun 2013 | A1 |
| 20130261576 | Strobech et al. | Oct 2013 | A1 |
| 20130267921 | Weston | Oct 2013 | A1 |
| 20130274688 | Weston | Oct 2013 | A1 |
| 20140018753 | Joshi et al. | Jan 2014 | A1 |
| 20140039423 | Riesinger | Feb 2014 | A1 |
| 20140114263 | Weston | Apr 2014 | A1 |
| 20140114268 | Auguste et al. | Apr 2014 | A1 |
| 20140135721 | Riesinger | May 2014 | A1 |
| 20140188059 | Robinson et al. | Jul 2014 | A1 |
| 20140330224 | Albert | Nov 2014 | A1 |
| 20140343519 | Weston | Nov 2014 | A1 |
| 20150100045 | Allen | Apr 2015 | A1 |
| 20150141941 | Allen | May 2015 | A1 |
| 20150173954 | Blott et al. | Jun 2015 | A1 |
| 20150209492 | Blott et al. | Jul 2015 | A1 |
| 20170007753 | Blott et al. | Jan 2017 | A1 |
| 20170156967 | Blott et al. | Jun 2017 | A1 |
| 20190099293 | Hall | Apr 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 1099850 | Apr 1981 | CA |
| 201076519 | Jun 2008 | CN |
| 3935818 | May 1991 | DE |
| 4016034 | Nov 1991 | DE |
| 19844355 | Apr 2000 | DE |
| 20301859 | Apr 2003 | DE |
| 202004018245 | Jul 2005 | DE |
| 0171268 | Feb 1986 | EP |
| 0521434 | Jan 1993 | EP |
| 0575090 | Dec 1993 | EP |
| 0669463 | Aug 1995 | EP |
| 0733375 | Sep 1996 | EP |
| 0858810 | Aug 1998 | EP |
| 0888141 | Jan 1999 | EP |
| 1007015 | Jun 2000 | EP |
| 1013290 | Jun 2000 | EP |
| 1029585 | Aug 2000 | EP |
| 1105171 | Jun 2001 | EP |
| 1105180 | Jun 2001 | EP |
| 1107813 | Jun 2001 | EP |
| 1030657 | Oct 2001 | EP |
| 1306123 | May 2003 | EP |
| 1440737 | Jul 2004 | EP |
| 1790378 | May 2007 | EP |
| 1880840 | Jan 2008 | EP |
| 1476217 | Mar 2008 | EP |
| 1923077 | May 2008 | EP |
| 2068257 | Jun 2009 | EP |
| 2111804 | Oct 2009 | EP |
| 2218431 | Aug 2010 | EP |
| 2462908 | Jun 2012 | EP |
| 1163907 | Oct 1958 | FR |
| 236350 | Jul 1925 | GB |
| 1334840 | Oct 1973 | GB |
| 1394171 | May 1975 | GB |
| 1400124 | Jul 1975 | GB |
| 1422171 | Jan 1976 | GB |
| 2037150 | Jul 1980 | GB |
| 1575266 | Sep 1980 | GB |
| 2047438 | Nov 1980 | GB |
| 2194446 | Mar 1988 | GB |
| 2235877 | Mar 1991 | GB |
| 2288734 | Nov 1995 | GB |
| 2307180 | May 1997 | GB |
| 2336546 | Oct 1999 | GB |
| 2371490 | Jul 2002 | GB |
| 2378392 | Feb 2003 | GB |
| 2378734 | Feb 2003 | GB |
| 2382989 | Jun 2003 | GB |
| 2418738 | Apr 2006 | GB |
| 2424582 | Oct 2006 | GB |
| 2435419 | Aug 2007 | GB |
| S6180018 | May 1986 | JP |
| 2005334188 | Dec 2005 | JP |
| 1578150 | Jul 1990 | SU |
| WO-9100718 | Jan 1991 | WO |
| WO-9209301 | Jun 1992 | WO |
| WO-9209651 | Jun 1992 | WO |
| WO-9212369 | Jul 1992 | WO |
| WO-9306802 | Apr 1993 | WO |
| WO-9309176 | May 1993 | WO |
| WO-9324083 | Dec 1993 | WO |
| WO-9420133 | Sep 1994 | WO |
| WO-9503018 | Feb 1995 | WO |
| WO-9640174 | Dec 1996 | WO |
| WO-9703717 | Feb 1997 | WO |
| WO-9711658 | Apr 1997 | WO |
| WO-9733922 | Sep 1997 | WO |
| WO-9742986 | Nov 1997 | WO |
| WO-9803267 | Jan 1998 | WO |
| WO-9806444 | Feb 1998 | WO |
| WO-9846818 | Oct 1998 | WO |
| WO-9901173 | Jan 1999 | WO |
| WO-9917698 | Apr 1999 | WO |
| WO-9919013 | Apr 1999 | WO |
| WO-9930629 | Jun 1999 | WO |
| WO-9947097 | Sep 1999 | WO |
| WO-9965536 | Dec 1999 | WO |
| WO-0017968 | Mar 2000 | WO |
| WO-0038752 | Jul 2000 | WO |
| WO-0061206 | Oct 2000 | WO |
| WO-0062827 | Oct 2000 | WO |
| WO-0064396 | Nov 2000 | WO |
| WO-0113853 | Mar 2001 | WO |
| WO-0162312 | Aug 2001 | WO |
| WO-0166017 | Sep 2001 | WO |
| WO-0185248 | Nov 2001 | WO |
| WO-0202079 | Jan 2002 | WO |
| WO-02083046 | Oct 2002 | WO |
| WO-02094256 | Nov 2002 | WO |
| WO-02102864 | Dec 2002 | WO |
| WO-03005943 | Jan 2003 | WO |
| WO-03022333 | Mar 2003 | WO |
| WO-03053346 | Jul 2003 | WO |
| WO-03057307 | Jul 2003 | WO |
| WO-03065877 | Aug 2003 | WO |
| WO-03073970 | Sep 2003 | WO |
| WO-03074100 | Sep 2003 | WO |
| WO-03101508 | Dec 2003 | WO |
| WO-2004016313 | Feb 2004 | WO |
| WO-2004018020 | Mar 2004 | WO |
| WO-2004037334 | May 2004 | WO |
| WO-2004054632 | Jul 2004 | WO |
| WO-2005006975 | Jan 2005 | WO |
| WO-2005009488 | Feb 2005 | WO |
| WO-2005017000 | Feb 2005 | WO |
| WO-2005018695 | Mar 2005 | WO |
| WO-2005046760 | May 2005 | WO |
| WO-2005046761 | May 2005 | WO |
| WO-2005046762 | May 2005 | WO |
| WO-2005082435 | Sep 2005 | WO |
| WO-2005091884 | Oct 2005 | WO |
| WO-2005102415 | Nov 2005 | WO |
| WO-2005105176 | Nov 2005 | WO |
| WO-2005105180 | Nov 2005 | WO |
| WO-2005118011 | Dec 2005 | WO |
| WO-2005123170 | Dec 2005 | WO |
| WO-2006014534 | Feb 2006 | WO |
| WO-2006030054 | Mar 2006 | WO |
| WO-2006034128 | Mar 2006 | WO |
| WO-2006052745 | May 2006 | WO |
| WO-2006052839 | May 2006 | WO |
| WO-2006056294 | Jun 2006 | WO |
| WO-2006089551 | Aug 2006 | WO |
| WO-2006100053 | Sep 2006 | WO |
| WO-2006114638 | Nov 2006 | WO |
| WO-2006135506 | Dec 2006 | WO |
| WO-2007003905 | Jan 2007 | WO |
| WO-2007013064 | Feb 2007 | WO |
| WO-2007019038 | Feb 2007 | WO |
| WO-2007030598 | Mar 2007 | WO |
| WO-2007030599 | Mar 2007 | WO |
| WO-2007031765 | Mar 2007 | WO |
| WO-2007050594 | May 2007 | WO |
| WO-2007062024 | May 2007 | WO |
| WO-2007085396 | Aug 2007 | WO |
| WO-2007087808 | Aug 2007 | WO |
| WO-2007087809 | Aug 2007 | WO |
| WO-2007092397 | Aug 2007 | WO |
| WO-2007106594 | Sep 2007 | WO |
| WO-2007124198 | Nov 2007 | WO |
| WO-2007133618 | Nov 2007 | WO |
| WO-2007133644 | Nov 2007 | WO |
| WO-2008014358 | Jan 2008 | WO |
| WO-2008036345 | Mar 2008 | WO |
| WO-2008041926 | Apr 2008 | WO |
| WO-2008076407 | Jun 2008 | WO |
| WO-2008082444 | Jul 2008 | WO |
| WO-2008100437 | Aug 2008 | WO |
| WO-2008129318 | Oct 2008 | WO |
| WO-2008131895 | Nov 2008 | WO |
| WO-2008131896 | Nov 2008 | WO |
| WO-2008134544 | Nov 2008 | WO |
| WO-2008134774 | Nov 2008 | WO |
| WO-2008141228 | Nov 2008 | WO |
| WO-2008141470 | Nov 2008 | WO |
| WO-2009019227 | Feb 2009 | WO |
| WO-2009019229 | Feb 2009 | WO |
| WO-2009034322 | Mar 2009 | WO |
| WO-2009042514 | Apr 2009 | WO |
| WO-2009047524 | Apr 2009 | WO |
| WO-2009052193 | Apr 2009 | WO |
| WO-2009060327 | May 2009 | WO |
| WO-2009062327 | May 2009 | WO |
| WO-2009066106 | May 2009 | WO |
| WO-2009068666 | Jun 2009 | WO |
| WO-2009070905 | Jun 2009 | WO |
| WO-2009078790 | Jun 2009 | WO |
| WO-2009103031 | Aug 2009 | WO |
| WO-2009124100 | Oct 2009 | WO |
| WO-2009126102 | Oct 2009 | WO |
| WO-2009126833 | Oct 2009 | WO |
| WO-2009145703 | Dec 2009 | WO |
| WO-2009146441 | Dec 2009 | WO |
| WO-2009156709 | Dec 2009 | WO |
| WO-2009158128 | Dec 2009 | WO |
| WO-2010033271 | Mar 2010 | WO |
| WO-2010051068 | May 2010 | WO |
| WO-2010142959 | Dec 2010 | WO |
| WO-2010147533 | Dec 2010 | WO |
| WO-2012131237 | Oct 2012 | WO |
| WO-2012140378 | Oct 2012 | WO |
| WO-2012146656 | Nov 2012 | WO |
| WO-2013010907 | Jan 2013 | WO |
| WO-2013083800 | Jun 2013 | WO |
| WO-2014016759 | Jan 2014 | WO |
| WO-2014020440 | Feb 2014 | WO |
| WO-2014020443 | Feb 2014 | WO |
| WO-2014108476 | Jul 2014 | WO |
| WO-2014113253 | Jul 2014 | WO |
| Entry |
|---|
| Bevan D., et al., “Diverse and potent activities of HGF/SF in skin wound repair,” Journal of Pathology, vol. 203, 2004, pp. 831-838. |
| Communication pursuant to Article 94(3) EPC for Application No. 08855752.5, mailed Mar. 9, 2012, 8 pages. |
| Communication pursuant to Article 94(3) EPC for Application No. 08856241.8, mailed Jul. 25, 2013, 3 pages. |
| Communication pursuant to Article 94(3) EPC for Application No. 08856241.8, mailed Mar. 8, 2011, 4 pages. |
| Communication pursuant to Article 94(3) EPC for Application No. 08856566.8, mailed Dec. 8, 2011, 4 pages. |
| Communication pursuant to Article 94(3) EPC for Application No. 08857939.6, mailed Mar. 8, 2011, 4 pages. |
| Communication pursuant to Article 94(3) EPC for Application No. 08857939.6, mailed Oct. 29, 2013, 3 pages. |
| English Translation of First Chinese Office Action for Chinese Application No. 200880117224.3 dated Jul. 4, 2012, 4 pages. |
| Info V.A.C. User Manual, KCI on Dec. 1, 2006 in 76 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2008/051070, mailed on Jun. 8, 2010, 5 pages. |
| International Preliminary Report on Patentability for Application No. PCTGB2008/051075, mailed on Jun. 8, 2010, 7 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2008/051114, mailed on Jun. 8, 2010. |
| International Preliminary Report on Patentability for Application No. PCT/GB2008/051122, mailed on Jun. 8, 2010, 5 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2008/051134, mailed on Jun. 8, 2010, 6 pages. |
| International Search Report for Application No. PCT/GB2008/051070, mailed on Feb. 27, 2009, 2 pages. |
| International Search Report for Application No. PCT/GB2008/051134 mailed on Apr. 3, 2009, 4 pages. |
| International Search Report for Application No. PCT/GB2008/051122, mailed on Feb. 27, 2009, 2 pages. |
| International Search Report for PCT Application No. PCT/GB2008/051075, mailed on Mar. 11, 2009, 2 pages. |
| Internationl Search Report for Application No. PCT/GB2008/051114, mailed on Apr. 8, 2009, 5 pages. |
| Landis E.M., et al., “The Effects of Alternate Suction and Pressure on Blood Flow to the Lower Extremities,” Alternate Suction and Pressure, J Clin Invest, Sep. 1993, vol. 12 (5), pp. 925-961. |
| Mitchell R.N., et al., “Role of Stem Cells in Tissue Homeostasis,” Pocket Companion to Robbins and Cotran Pathologic Basis of Disease, 7th Edition, 2006, p. 55 (3 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20220241113 A1 | Aug 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13545942 | Jul 2012 | US |
| Child | 14855214 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16115064 | Aug 2018 | US |
| Child | 17673673 | US | |
| Parent | 14855214 | Sep 2015 | US |
| Child | 16115064 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12746504 | US | |
| Child | 13545942 | US | |
| Parent | 12746508 | US | |
| Child | 13545942 | US | |
| Parent | 12746757 | US | |
| Child | 13545942 | US | |
| Parent | 12746753 | US | |
| Child | 13545942 | US | |
| Parent | 12746751 | US | |
| Child | 13545942 | US |
